Clinical Trial Update: Intravesical Adjuvant Electromotive Mitomycin-C [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update announcing completion of Phase 2/3 evaluation of intravesical adjuvant electromotive delivery of mitomycin-C for bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1 | Phase 2, Phase 3 | Status: COMPLETED